Genmab AS

Genmab AS Equity Growth

The Year-over-Year Equity Growth of Genmab AS (GMAB) as of Nov 22, 2026 is -84.10 %. In the previous year, Year-over-Year Equity Growth was 16.09 % — a change of -622.61% (lower).

Equity Growth

-84.10 %

YoY

-622.61%

Last updated:

Year-over-Year Equity Growth of Genmab AS is 2025 -84.10 % . Year-over-Year Equity Growth of Genmab AS was 2024 16.09 % . It decreases by -622.61% lower compared to the previous year.

The Genmab AS Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
27.78 USD
Jan 1, 2019
75.29 USD
Jan 1, 2020
36.11 USD
Jan 1, 2021
16.08 USD
Jan 1, 2022
22.91 USD
Jan 1, 2023
15.86 USD
Jan 1, 2024
16.09 USD
Jan 1, 2025
-84.10 USD
The Genmab AS Equity Growth history
YEAREquity GrowthYoY
-84.10 %-622.61%
16.09 %+1.44%
15.86 %-30.77%
22.91 %+42.48%
16.08 %-55.47%
36.11 %-52.03%
75.29 %+171.04%
27.78 %-7.25%
29.95 %-22.07%
38.43 %-46.26%
71.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Year-over-Year Equity Growth of Genmab AS is -84.10 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Genmab AS

All Key Metrics — Genmab AS